Eris Lifesciences Ltd · NSE:ERIS

Eris Lifesciences — Q2 FY18 Earnings Presentation

16 slides from Eris Lifesciences's earnings presentation, November 2017

  1. Slide 1: Q2 FY18 Investor Presentation

    Q2 FY18 Investor Presentation

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions

  3. Slide 3: Section 1: Key Financial Highlights

    Section 1 Key Financial Highlights

  4. Slide 4: H1 FY 2018: Key Financial Highlights

    H1 FY 2018 : Key Financial Highlights Q1 Q2 H1 Revenues from Operations 3813 4344 1824 1852 1989 2492 Q1FY17 Q1FY18 Q2FY17 Q2FY18 H1FY17 H1FY18 YoY Growth 1.5% 25.3% 13.9% EBIDTA 1475 1692 736 714 739 978 Q1FY17 Q1FY18 Q2FY17 Q2FY18 H1FY17 H1FY18 YoY Growth -2.9% 32.3% 14.7% PAT 929 1637 624 708 690

  5. Slide 5: Section 2: Business Overview

    Eris Business Overview Section 2

  6. Slide 6: H1 FY 2018: Revenue comparison of Eris with IPM

    Our business segments H1 FY 2018 : Revenue comparison of Eris with IPM IPM Eris Lifesciences Ltd 4,471 5,83,865 2.0% 5,95,517 4,095 9.2% 1,615 1,412 14.3% Acute 3,90,068 -0.05% 3,89,885 Acute Chronic 2,682 6.5% 2,856 Chronic 6.1% 1,93,797 2,05,632 YoY Growth H1 FY 17 H1 FY 18 H1 FY 17 YoY Growth H1

  7. Slide 7: Our business segments

    Our business segments Chronic Specialty Acute Revenue  INR 5491 MN (FY 17)/ INR 2856MN (H1 FY 18)  INR 2885 MN (FY 17)/ INR 1615 MN (H1 FY 18) Contribution  65.6%(FY 17)/ 63.9%(H1 FY 18)  34.4%(FY 17)/ 36.1%(H1 FY 18)  Revenue CAGR(FY 13-17) : 28.9%  Revenue CAGR(FY 13-17) : 12.0%  H1 FY18 Yo

  8. Slide 8: Strong brand & Specialty focus

    Strong brand & Specialty focus Top 10 Mother brands revenue contribution IPM Prescription contribution IPM Top 25 48.0% Co Avg 38.5% 61.5% Eris 72.5% Specialists & Super Specialists Top 25 mother brands revenue contribution ERIS Prescription contribution IPM Top 25 3.3% 69.2% Co Avg Eris 92.2% 96.7%

  9. Slide 9: Superior lifecycle profile of brands vis-à-vis IPM

    Superior lifecycle profile of brands compared to the IPM Superior lifecycle profile of brands vis-à-vis IPM Prescription contribution from lifecycle stages of pharmaceutical molecules constituting product portfolio of respective companies (1) 47% 47% 39% 44% 42% 36% 31% 29% 65% 34% 31% 26% 26% 49% 4

  10. Slide 10: Our Top 10 Brands

    Strong brand focus Our Top 10 Brands (Market share in FY2017) (Prescription rank FY2017) (CAGR 5 Yr FY 13-17)  Our Top 10 brands have leading Glimisave 5.5% #3 29.0% market position in their respective Therapeutic Areas Eritel 5.3% 28.5% #4 Rabonik 4.4% #10 9.2% Remylin 6.3% #8 10.2% Tayo 4.9% #5 7

  11. Slide 11: Section 3: Financial Performance & Business Strategy

    Section 3 Financial Performance & Business Strategy

  12. Slide 12: Company Productivity: H1 FY 18

    Company Productivity : H1 FY 18 Sales Revenues 7250 4344 FY 17 H1 FY18 Medical Representatives 1501 1679 FY 17 H1 FY18 Field Managers 696 755 FY 17 H1 FY 2018 Yield per man per Month 4.0 4.3 FY 17 H1 FY 2018  Yield per man per month in INR lakhs  Revenue in INR MN

  13. Slide 13: Financial Performance: H1 FY 2018

    Financial Performance : H1 FY 2018 Q1 Q2 H1 Revenues from Operations 3813 4344 1824 1852 1989 2492 Q1FY17 Q1FY18 Q2FY17 Q2FY18 H1FY17 H1FY18 YoY Growth 1.5% 25.3% 13.9% EBIDTA 1475 1692 736 714 739 978 Q1FY17 Q1FY18 Q2FY17 Q2FY18 H1FY17 H1FY18 YoY Growth -2.9% 32.3% 14.7% PAT 929 1637 624 708 690 13

  14. Slide 14: Financial Performance: H1 FY 2018

    Financial Performance : H1 FY 2018 Revenues from Operations EBITDA 2,686 CAGR 16.5% 7,250 5,970 CAGR 33% 5,456 1,715 1,692 5,088 3,931 4,344 1,215 859 989 FY13 FY14 FY15 FY16 FY17 H1 FY18 FY13 FY14 FY15 FY16 FY17 H1 FY18 PAT EPS CAGR 42.8% 2,421 17.61 1,637 11.91 * 1,336 9.71 892 6.49 582 704 4.23 5

  15. Slide 15: Top 10 Institutional Investors as on 30th Sep 2017

    Top 10 Institutional Investors as on 30th Sep 2017 3.45% 2.95% 2.16% 1.65% 1.30% 1.08% 1.01% 0.97% 0.83% 0.65% BIRLA SUN LIFE TRUSTEE COMPANY SBI MUTUAL FUND MOTILAL OSWAL MUTAL FUND GOLDMAN SACHS INDIA LIMITED MORGAN STANLEY DSP BLACKROCK MUTUAL FUND ABU DHABI INVESTMENT AUTHORITY - BEHAVE IDFC MER

  16. Slide 16: Way Forward

    Way Forward Future Patent Strategic Consolidate Expand In-Licensing Expiries Acquisitions • Leverage our • Identified 6 key • Acquired majority • New Categories • Lifestyle/ Chronic existing sales, products in stake in Kinedex within existing portfolio marketing, Cardiovascular and Healthcare Pvt. T

Eris Lifesciences — Q2 FY18 Earnings Presentation on 6ix